Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Nov-Dec;40(6):1104-1106.
doi: 10.1111/pde.15336. Epub 2023 May 23.

A child with CARD14-associated papulosquamous eruption (CAPE) successfully treated with ustekinumab

Miguel Nogueira  1 , Joel Reis  1 , Maria Abreu  2 , André Coelho  3 , Cláudia F Reis  2 , Susana Machado  1
Affiliations
Case Reports

A child with CARD14-associated papulosquamous eruption (CAPE) successfully treated with ustekinumab

Miguel Nogueira et al. Pediatr Dermatol. 2023 Nov-Dec.

Abstract

CARD14-associated papulosquamous eruption (CAPE) is a rare inflammatory skin eruption that can have features of psoriasis, pityriasis rubra pilaris, and erythroderma. This skin condition is known for its resistance to topical or conventional systemic therapies. Successful treatment of CAPE with anti-IL-12/IL-23 and IL-17 inhibitors has been reported. We present a case of a 2-year-old girl with CAPE who was successfully treated with ustekinumab.

Keywords: erythroderma; pediatric; ustekinumab.

PubMed Disclaimer

References

REFERENCES

    1. Craiglow BG, Boyden LM, Hu R, et al. CARD14-associated papulosquamous eruption: a spectrum including features of psoriasis and pityriasis rubra pilaris. J Am Acad Dermatol. 2018;79(3):487-494. doi:10.1016/J.JAAD.2018.02.034
    1. Frare CP, Blumstein AJ, Paller AS, et al. CARD14-associated papulosquamous eruption (CAPE) in pediatric patients: three additional cases and review of the literature. Pediatr Dermatol. 2021;38(5):1237-1242. doi:10.1111/PDE.14779
    1. Jordan CT, Cao L, Roberson EDO, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012;90(5):784-795. doi:10.1016/J.AJHG.2012.03.012
    1. Pruszkowski A, Bodemer C, Fraitag S, Teillac-Hamel D, Amoric JC, De Prost Y. Neonatal and infantile erythrodermas: a retrospective study of 51 patients. Arch Dermatol. 2000;136(7):875-880. doi:10.1001/ARCHDERM.136.7.875
    1. Signa S, Campione E, Rusmini M, et al. Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab. Pediatr Rheuumatol Online J. 2019;17(1):38. doi:10.1186/S12969-019-0336-3

Publication types

LinkOut - more resources